Zak Mir's prediction is 5 p at the end of February (correction of my previous post 514 saying 5 p by the end of next month). He is right most of the time. |
Carolyn Rand doubled up yesterday. |
Link please? |
Zak Mir has today predicted that the share price will rise to 5 p by the end of next month. |
This is one of the cheapest stocks in the entire LSE. Safe and sound with plenty of cash and a growing business. |
They are now asking 4.2p for size verses the 4p offer price. Always a good sign. |
Gentlemen
The Gracious Fellow does not usually take note of broker waffle however Cavendish have to be complemented on their excellent research, they retain their target price of 10p per share in the last note.
Recent director buying is worthy of comment also.
It does look like the stock price is poised for a move, that move could be dynamic as the market anticipates a very positive H2 and growth ahead.
A material revaluation of Cambridge is imminent. |
Time is right to get back in here or add, the company is materially undervalued at £8m m/cap with cash of £5m.
The entire business is in for nothing and it's generating £10m revenues per year, growing, profitable and excellent margins.
Broker retains 10p target price. |
This was trading in the 4p's and looking to go higher after the DHSS settlement that restored £2.5m of cash back to the treasury. It moved from 2.8p to 4.2p in two sessions last month but fell back on profit taking.
The message being sent by the recent BOD share purchases is they deem the stock cheap and more importantly imply the recent court summons (not being charged btw) is of irrelevance.
The opportunity to buy has never been better given that 2nd half sales are expected to be strong. |
They're only small purchases though bomber. |
Back here rather than still here ALS !
Methinks the non-exec Chair is telling us it's right to be here as well . |
Bomber
Are you still here. I hope you made a profit on these on the rise up to a quid. Take a look at AGL I feel it's a very much better opportunity. |
I know the non-exec Chair bought a pitiful amount of stock yesterday , but -
1) It amounts to her ONLY beneficial holding .
2) CNS will shortly go into close season for their end March financial year .
3) After the excellent DHSS news , the recent summons has created some uncertainty .
4) We are overdue news on whether the interim CEO is to become permanent .
Even though it also means that we are not currently in takeover talks , I take the Chair's tiny purchase as a humungous thumbs up . |
Looks like the shorting scumbags are working this again, continued tiny sells hitting the bid, usually timed early morning and at the close. The LSE BB full of bashers who work 24/7, nothing new to AIM over recent years.
Looks like they are 'inside' also, they clearly had time to close their positions ahead of the Gov settlement news.
Hopefully they will get another bloody nose soon enough, there has been a lot of very positive news coming out of this sector over recent times including takeover approaches. |
Gentlemen
The Gracious Fellow points out that the last RNS was hardly worthy of delivery to the market, a good CEO would have blocked it, instead we have a rather wet behind the ears fellow who probably knows no better, this is not to suggest Cooper is poor from a hands on business perspective, he has clearly delivered significant profitability and margin increase.
Moving on it is worth pointing out that Cavendish (broker) have not even bothered to review the court summons, as the above poster points out the charge (which is a minuscule affair in any-case) effects a third party.
Once again for the benefit of doubt the Gracious Fellow is long Cambridge and would add that market dynamics will move the share price significantly in due course.
Also note the recent sector M&A activity which has been priced way above market levels.
CNSL is a BUY. |
Those who sold on the rather irrelevant RNS will be kicking themselves, CNSL have only been summoned to attend court proceedings, in actual fact it is Novacyt (NCYT) who have actually been charged.
The matter is broadly irrelevant to CNSL, at the very worst a very modest fine might occur, although extremely unlikely.
The share price hit 4.2p bid on the 17th, you can now buy in at 3.7p, I have a feeling a few sold out on the dynamic move from 2.8p to 4.3p mid price however the indicators remain exceptionally bullish.
Broker target remains at 10p. |
It was just a notion. Phone them and ask?
I was struck by the coincidence of timing, almost as if someone is blowing smoke after the settlement RNS which lifted the share price 30% and caught shorters short. |
They wouldn't issue an RNS if it were a parking penalty notice, would they? |
Probably obligatory. Market sensitive, but pro-forma. Buying opportunity. |
Do not take your eyes off the larger picture here just because the share price has dropped back a little, no doubt buyers picking up shares around 3p have sold for profit as indicators became toppy, the mid term 'goal' remains a material re-rate.
I would not be surprised to see a trading update shortly either.
A very positive year ahead, as such the target price of 10p a share could easily occur. |
Please excuse me to use the phrase that every dog has its day. This is the year of transformational change for CNSL.
Let's imagine if an ordinary person has won a £1 million in a prize draw. That's life changing. The same applies to CNSL, which can now legitimately own that £2.5 million cash without a cloud overhanging its head. Litigation is time consuming, distracting and quite often frustrating. It is negative energy.
Management can now get on with the business with positive energy, unhindered. The company ticks all the boxes for investing in. A strong BUY. |
 Post the settlement of the interminable DHSS dispute , the house broker , Cavendish , may have made no changes to their 10p target share price , their £8.8m revenue forecast for the year to end March 2025 , their expectation of positive adjusted EBITDA of £0.4m , and their forecast of £5m net cash , but what is quite interesting , and perhaps quite significant , is a subtle change of wording in their final paragraph entitled " Investment Thesis " .
The two house analysts are exactly the same , and the paragraph itself is exactly the same as the one written on 26th November , 2024 after the company's interim results , but for two small changes -
1) " We believe FY24 might be regarded as a PIVOTAL year for CNS " as opposed to " watershed " year beforehand .
2) the final sentence states " With the stock currently trading on an EV/Sales of just 0.2x , we believe this represents compelling value , considering the level of growth potential that could be unlocked from the fast-growing and lucrative food sensitivity testing market , WHICH APPEARS TO BE NOTABLY GAINING INCREASED MAINSTREAM MARKET ACCEPTANCE " . This latter comment in capitals has now been added .
Given that the company would have had some input into Cavendish's comments , and that we are now 3 1/2 months into the company's second-half as opposed to just 2 months in after the interims , surely these subtle changes should give us even more confidence in the full year outcome and beyond ? |
Usual market maker games, at best only on most platforms, shut off online buying once again making stock hard to access. |
Asking 4.7p for just £7k of shares now, all technical indicators are bullish.
Worth noting the low share count only 237m and no dilution ahead as the company holds cash of £4.75m
Current m/cap just £9.5m |
Book exceptionally strong this morning, the break through 4p is very meaningful, last weeks settlement with the DHSS was a material event.
Also the broker re-iterated their 10p target price last week. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
